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Background: One vital therapeutic approach for the treatment of type 2 diabetes mellitus is the use of agents that
can decrease postprandial hyperglycaemia by inhibiting carbohydrate digesting enzymes. The present study
investigated the effects of bioassay-guided extract and fractions of the dried fruit pericarp of Phaleria macrocarpa,
a traditional anti-diabetic plant, on α-glucosidase and α-amylase, in a bid to understand their anti-diabetic
mechanism, as well as their possible attenuation action on postprandial glucose increase.
Methods: Methanol extract (ME), obtained by successive solvent extraction, its most effective liquid-liquid
n-butanol fraction (NBF) and the flash column chromatographic sub-fraction (SFI), were evaluated for in vitro
α-glucosidase (yeast) and α-amylase (porcine) activity inhibition. Furthermore, confirmatory in vivo tests were carried
out in streptozotocin-induced diabetic rats (SDRs) using oral glucose, sucrose and starch tolerance tests.
Results: At the highest concentration employed (100 μg/ml), NBF showed highest inhibition against α-glucosidase
(75%) and α-amylase (87%) in vitro (IC50 = 2.40 ± 0.23 μg/ml and 58.50 ± 0.13 μg/ml, respectively) in a dose-dependent
fashion; an effect found to be about 20% higher than acarbose (55%), a standard α-glucosidase inhibitor (IC50 = 3.45 ±
0.19 μg/ml). The ME and SFI also inhibited α-glucosidase (IC50 = 7.50 ± 0.15 μg/ml and 11.45 ± 0.28 μg/ml) and
α-amylase (IC50 = 43.90 ± 0.19 μg/ml and 69.80 ± 0.25 μg/ml), but to a lesser extent. In in vivo studies with diabetic rats,
NBF and SFI effectively reduced peak blood glucose (PBG) by 15.08% and 6.46%, and the area under the tolerance
curve (AUC) by 14.23% and 12.46%, respectively, after an oral sucrose challenge (P < 0.05); thereby validating the
observed in vitro action. These reduction effects on PBG and AUC were also demonstrated in glucose and starch
tolerance tests, but to a lesser degree.
Conclusions: These findings reveal that P. macrocarpa can attenuate hyperglycaemia in both in vitro and in vivo
conditions by potently inhibiting carbohydrate hydrolysing enzymes, making it a viable plant for sourcing natural
compounds for the management of type 2 diabetes mellitus.
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Plants have been exemplary sources of medicine since
ancient times. They have played key roles in traditional
health care systems and on the basis of this, have be-
come a significant percentage of allopathic and modern
drugs in many nations of the world [1,2]. Medicinal
plants are therefore used as modern alternatives to
orthodox medicines or as complementary products to
maintain health or treat aspects of diseases, particularly
where conventional medication has had only limited
success [3].
Diabetes is one such disease that has been managed
with only limited success by “Western” medicine. Con-
ventional effort at better management of diabetes has
been disappointing and the control of blood glucose
level remains unsatisfactory, as reflected in daily
increases in morbidity and mortality rates [4]. Conse-
quently, the current focus for appropriate anti-diabetic
agents is herbal medicine. There is, however, a need for
more in-depth investigation to confirm and advocate the
benefits of these plants over existing therapies, including
elucidation of their mechanism(s) of action and thera-
peutic effects, as the anti-diabetic evidence is often anec-
dotal [5].
Phaleria macrocarpa (Scheff ) Boerl (Thymelaceae),
a shrub known locally as Mahkota Dewa, literally
translated as “God’s Crown”, has for centuries been used
by the native Indonesians and the lower course of
Malaysia to combat diabetes, liver diseases, vascular
problems, cancer, and high blood pressure [6]. The parts
of P. macrocarpa that are used for medicinal treatments
are the stems, leaves and fruits. Although the works of
Triastu and Choi [7] and Triastu et al. [8] on oxidative
stress protection in alloxan diabetes suggest scientific
validation of its anti-diabetic activity, there are no
reports, to our knowledge, on the detailed anti-diabetic
mechanism of P. macrocarpa. Earlier exploratory studies
with young and old fruit extracts of P. macrocarpa on
non-diabetic rats [9], and later with young and old leaf
extracts [10] suggested that P. macrocarpa possessed
possible α-glucosidase inhibitory activity.
It was therefore necessary to conduct a detailed study
with the aim to understand at least in part, the anti-
diabetic mechanism of P. macrocarpa as it relates to in-
hibition of carbohydrate hydrolysis since drugs with this
property can circumvent postprandial hyperglycaemic
risk in diabetes. In vitro studies are relatively simple,
precise and most suitable when a large number of
compounds or fractions are to be tested, and are also
used in mechanistic elucidation [11]. However, a con-
firmatory in vivo test is also necessary to substantiate
positive in vitro results, since positive α-glucosidase in-
hibitory action may not always correlate with in vivo
actions [12]. Accordingly, the present study employedboth in vitro and in vivo test procedures to evaluate the
effect of P. macrocarpa on carbohydrate digesting
enzymes. Moreover, the studies also followed a
systematized drug discovery program of bioassay-guided
extraction and test procedures. An activity-guided ap-
proach is indispensable in natural product discovery or
standardization of herbal products for use as alternatives
and/or complements to conventional medicines.
The present study evaluated the in vitro inhibition of
yeast α-glucosidase (EC 3.2.1.20) and porcine pancreatic
α-amylase (EC 3.2.1.1) activities of the active crude
extract, fraction and sub-fraction of P. macrocarpa iden-
tified earlier from activity-guided hypoglycaemic and
anti-hyperglycaemic tests carried out in our laboratory
[13,14]. A confirmatory in vivo study was also conducted
in non-diabetic and streptozotocin-induced diabetic rats.
Methods
Preparation of plant extracts and fractions
Fruits of Phaleria macrocarpa were collected from
Kepala Batas, Seberang Perai, Pulau Pinang, Malaysia
in August, 2010. They were identified by Mr. V.
Shunmugam a/l Vellosamy and a voucher specimen of the
plant (voucher number 11259) was deposited in the
herbarium unit, School of Biological Sciences, Universiti
Sains Malaysia. The pericarps of the fruits were sliced,
dried, and powdered using a milling machine. About
2,400 g were successively extracted with petroleum ether
and methanol using Soxhlet apparatus (40°C) for 48 h
each. Thereafter, the residue from the methanol extraction
after complete drying was extracted with water by macer-
ation at 60°C for 24 hours. Extraction with each solvent
was done in triplicate and the extracts obtained were
filtered with Whatman No. 1 filter paper and concentrated
in vacuo by rotary evaporation (Buchi Labortechnik,
Flawil, Switzerland). The concentrated extracts were
finally lyophilized to obtain 73.6 g (3.06%), 445.36 g
(18.55%) and 146 g (6.08%) each of dried petroleum ether
extract (PEE), methanol extract (ME) and water extract
(WE), respectively. Earlier results from hypoglycaemic and
anti-hyperglycaemic tests with these extracts showed that
the methanol extract was the most effective in lowering
blood glucose [13], and thus this alone was used in the
present study.
Successive liquid-liquid fractionation of the methanol
extract
The methanol extract of Phaleria macrocarpa was
fractionated with polarity graded solvents in separating
funnels. In brief, 110 g of the methanol extract was first
extracted with 3 × 360 ml of chloroform-water (6:5). The
combined chloroform fractions were dried with anhyd-
rous sodium sulphate and further concentrated in a ro-
tary evaporator. The aqueous layer was extracted with
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fractions were concentrated as above. Finally, the aque-
ous layer was extracted with n-butanol 5 × 250 ml and
the combined n-butanol fraction was concentrated as well
as the remaining aqueous fraction. The concentrated
fractions were thereafter freeze-dried to obtain 18 g
(5.45%), 24.3 g (7.36%), 110.1 g (33.3%) and 89.1 g (27%)
of chloroform (CF), ethyl acetate (EAF), n-butanol
(NBF) and aqueous (AF) fractions, respectively. Previ-
ous results from the hypoglycaemic and anti-
hyperglycaemic tests with these fractions revealed that
the n-butanol fraction was the most effective [14], and
hence this alone was selected for the present
investigation.
Fractionation of the active n-butanol fraction by dry-column
flash chromatography
A chromatographic glass column (27 × 5 cm) used in the
separation was gently loaded with 100 g of silica gel
(Merck, 7730) in 300 ml petroleum ether. The silica was
carefully packed by applying vacuum suction, and a
levelled and well-compacted bed yield was ensured. The
n-butanol fraction (12 g) was pre-adsorbed onto the
adsorbent (silica gel, 200-400 mesh) by first dissolving in
methanol (100 ml), followed by addition of the silica gel
(24 g). The mixture was evaporated to dryness using a ro-
tary evaporator, and the resultant dried extract-adsorbent
mixture was then loaded onto the top of the already
packed column evenly by applying suction. The column
was first eluted with 2 × 300 ml 100% chloroform,
followed serially by 2 × 300 ml chloroform-methanol in
graded ratios: (9:1), (8:2), (7:3), (6:4), (5:5), (4:6), (3:7),
(2:8), (1:9), (0:10) and finally with chloroform-methanol
-water (7:13:2). Fractions were collected in a fixed volume
and examined with thin layer chromatography using n-
butanol-acetic acid-water (4:1:5) as the mobile phase.
Fractions with similar profiles were pooled together offering
two sub-fractions namely SFI and SFII which were freeze-
dried to obtain 20 g (40%) and 8 g (16%) respectively.
When these sub-fractions were subjected to hypoglycaemic
and anti-hyperglycaemic screening, sub-fraction I was
found to be the most active [14], therefore it was used for
the current α-glucosidase and α-amylase inhibition tests.
Animals
Healthy male Sprague Dawley (SD) rats weighing 200-
250 g obtained from the Animal Research and Service
Centre, Universiti Sains Malaysia (USM) were used for
this study. These were housed in the Animal Transit
Room, School of Pharmaceutical Sciences, USM. They
were allowed free access to food (standard laboratory
chow, Gold Coin Sdn. Bhd., Malaysia) and tap water.
The animals were maintained according to accepted
international and national guidelines and the procedurefor this experiment approved by the Animal Ethics Com-
mittee of Universiti Sains Malaysia, Penang, Malaysia
(AECUSM). Diabetes was induced in the rats by intra-
peritoneal injection of 65 mg/kg b.w. of streptozotocin
(Sigma, St Louis, MO, USA), after an overnight fast [15].
Seventy-two (72) hours after, their blood glucose levels
were measured using the Accu-check Advantage II
Glucose meter (Roche Diagnostics Co., USA) and rats
with fasting blood glucose ≥ 15 mmol/L were considered
diabetic and included in the study. The effects of P.
macrocarpa extract, fraction and sub-fraction on oral
carbohydrate tolerance (starch, sucrose and glucose), an
indirect measure of α-glucosidase and α-amylase activities,
were evaluated in non-diabetic rats (NDRs) and
streptozotocin diabetic rats (SDRs) categorized into
groups as shown below. Acarbose, a conventional α-
glucosidase inhibitor, was used as a positive control in the
two sets of experiments.
In vitro α-glucosidase (EC 3.2.1.20) inhibition study
The assay was performed using our earlier procedure [11].
In brief, 50 μl of 4 graded concentrations (100 μg/ml,
50 μg/ml, 25 μg/ml, 12.5 μg/ml) each of sample (extract/
fraction/sub-fraction) and acarbose, the positive control,
were suspended in 100 μl of 0.1 M phosphate buffer
(pH 6.9) containing yeast α-glucosidase (Sigma Aldrich
Chemical Co, USA) solution (1.0 U/L) and pre-incubated
in a 96-well microplate at 25°C for 10 min. After
pre-incubation, 50 μl of 5 mM p-nitrophenyl-α-D-
glucopyranoside solution (the enzyme substrate), in 0.1 M
phosphate buffer (pH 6.9) was added to each well. An
equivalent volume (50 μl) of buffer solution was added to
the blank or control in place of the extract. The reaction
mixtures were incubated at 25°C for 5 min. The absorb-
ance of the reaction mixtures before and after substrate
incubation was measured at 405 nm on a micro-plate
reader (Power Wave Biotek Instrument Inc, USA). The
α-glucosidase inhibitory activity was calculated from the
difference in the two absorbances and expressed as %
inhibition as follows:
% Inhibition ¼ A 540 controlð Þ  A540 extractð Þ
A540 controlð Þ  100
The experiment was performed in triplicate. The IC50,
i.e. the concentration of the extract/fraction/acarbose
resulting in 50% inhibition of the enzyme was calculated
by regression analysis.
In vitro α-amylase (EC 3.2.1.1) inhibition study
A total of 500 μl of each sample and 500 μl of 0.02 M
sodium phosphate buffer (pH 6.9) containing porcine α-
amylase solution (0.5 mg/ml) were incubated at 25°C for
10 min. After pre-incubation, 500 μl of 1% starch
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was added to each test tube. The reaction mixtures were
then incubated at 25°C for 10 min and thereafter
stopped by addition of 1 mL of 3,5-dinitrosalicylic acid
(DNS) colour reagent. The test tubes were then
incubated in boiling water for 5 min and then cooled to
room temperature. After dilution of the reaction
mixtures with 10 ml of distilled water, the absorbance
was measured at 540 nm. Acarbose was used as the
positive control. The inhibition activity was calculated as
follows:
% Inhibition ¼ A 540 controlð Þ  A540 extractð Þ
A540 controlð Þ  100
Control incubations representing 100% enzyme activity
were carried out in a similar fashion by replacing the
plant extract/fraction with vehicle (500 μl DMSO and
distilled water). For the blank incubation, the enzyme so-
lution was replaced with distilled water and the same
procedure was followed as above. Separate incubations
conducted for the reaction of t = 0 min was performed by
adding samples to the DNS solution immediately after
addition of the enzyme. The experiment was also per-
formed in triplicate and the IC50, i.e. the concentration of
the extract/fraction/acarbose resulting in 50% inhibition of
the enzyme was calculated by regression analysis.
Confirmatory in vivo studies in non-diabetic rats (NDRs)
Starch tolerance test
In this test, 30 overnight-fasted non-diabetic rats divided
into five groups of six each were respectively treated (p.o.)
with ME (1 g/kg), NBF (1 g/kg), SFI (1 g/kg), acarbose
(positive control, 10 mg/kg), and distilled water (negative
control). Ten minutes after, the rats were administered
starch (3 g/kg body weight) orally and blood was collected
via tail puncture for blood glucose estimation before
(0 min) and at 30, 60 and 120 minutes after starch treat-
ment [16]. The recorded blood glucose concentrations
peak blood glucose (PBG) and area under curve (AUC)
were determined. Whereas the maximum blood glucose
concentration for each group was taken as PBG for the
group, AUC was calculated using the relationship:






Where BG represents the blood glucose concentration
measured at time intervals 0, 30, 60 and 120 minutes.Sucrose tolerance test
The sucrose tolerance test was carried out using the
same procedure as for the determination of starch toler-
ance. However, in this test, sucrose at a dose of 4 g/kg
body weight was used instead of starch.
Glucose tolerance test
The oral glucose tolerance test was also carried out
using the same procedure as for the determination of
starch tolerance, but glucose at a dose of 2 g/kg body
weight was used instead of starch.
Confirmatory in vivo tests using streptozotocin-induced
diabetic rats (SDRs)
This second set of tests also evaluated the effects of the ac-
tive methanol extract (ME), fraction (NBF) and sub-
fraction (SFI) on the tolerance of diabetic rats to orally
administered starch, sucrose or glucose. In each test, 5
groups of rats (n = 6) were treated as follows. Groups 1-3
were treated with 1 g/kg each of ME, NBF and SFI, re-
spectively and groups 4 (positive control) and 5 (negative
control) were treated with acarbose (10 mg/kg) and an
equivalent volume of distilled water (p.o.), respectively. As
in earlier tests, 10 minutes after oral starch (3 g/kg)/
sucrose (4 g/kg)/glucose (2 g/kg) treatment, blood glucose
was measured at 0, 30, 60 and 120 min and used for PBG
and AUC determinations similar as described above.
Statistical analysis
Data are expressed as mean ± SEM. Analysis of variance
(ANOVA) followed by post hoc analysis (Dunnett’s test)
were used for data analysis using the SPSS statistical
package, version 17.0. Differences at P < 0.05 were
considered significant.
Results
In vitro inhibition of α-glucosidase activity
The methanol extract (ME), n-butanol fraction (NBF)
and sub-fraction 1 (SFI) of P. macrocarpa potently
inhibited α-glucosidase activity in vitro in a dose-
dependent manner (Figure 1). At the highest concentra-
tion (100 μg/ml), NBF showed the highest percentage
α-glucosidase inhibition of about 75%. This was 20%
higher than that of acarbose (55%), a standard α-glucosidase
inhibitor. The corresponding maximum inhibitory ac-
tivities of the ME and SFI at the same concentrations were
32% and 20% respectively. This relative α-glucosidase
inhibition was clearly indicated by the IC50 values (the
concentration required for 50% inhibition) of each test
analyte (Table 1). NBF with the highest inhibitory activity
has lowest IC50 of 2.40 ± 0.23 μg/ml, closely followed by
acarbose (3.40 ± 0.19 μg/ml). The methanol extract and
SFI had IC50 values of 7.50 ± 0.15 μg/ml and 11.45 ±
0.28 μg/ml respectively.
Figure 1 Inhibitory effect of extract/fractions of P. macrocarpa fruit pericarp and acarbose on yeast α-glucosidase activity. The test was
performed in triplicate; values (% enzyme activity) are the mean ± SEM. ME: Methanol extract, NBF: n-Butanol fraction, SFI: Sub-fraction 1.
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Figure 2 shows the % inhibition of α-amylase activity by
ME, NBF and SFI along with the effect of acarbose. The
standard drug, acarbose exerted the most potent inhibi-
tory action against α-amylase of about 90% at 100 μg/
ml. The inhibition by the extract and fractions were
dependent on the concentrations/dose used. The metha-
nol extract and NBF exerted similar peak inhibition ac-
tivity of 87% while SFI inhibited α-amylase by 67% at the
highest concentration used (100 μg/ml). The inhibition
pattern also followed suit at lower concentrations.Effect of treatments on glucose tolerance tests in non-
diabetic and diabetic rats
Table 2 and Figures 3 and 4 show the effect of ME, NBF
and SFI of P. macrocarpa on glucose tolerance in NDRs
and SDRs. All treatments reduced the PBG in NDRs 30 -
minutes after oral glucose load, but only the reductions
caused by SFI (30.34%) and acarbose (26.97%) wereTable 1 IC50 values for yeast α-glucosidase and α-amylase
inhibition
Analyte Inhibitory concentration, IC50 (μg/ml)
α-glucosidase α-amylase
Methanol extract (ME) 7.50 ± 0.15 43.9 ± 0.19
n-butanol fraction (NBF) 2.40 ± 0.23 58.5 ± 0.13
Sub-fraction I (SFI) 11.45 ± 0.28 69.8 ± 0.25
Acarbose (ACAR) 3.40 ± 0.19 32.0 ± 0.30significant compared with the NCs. There was also a
corresponding significant decrease of AUC in the 4
treatment groups compared with the control (P < 0.05),
implying an onward flattening of the glucose tolerance
curves (Figure 3). In the SDRs, the ME failed to exert
any observable effect on the tolerance level following
oral glucose loading. The NBF and SFI showed non-
significant decreases in PBG levels (2.69% and 9.44%)
and AUCs (7.21 and 13.40%) respectively. The control
compound acarbose exerted a significant reduction of
the PBG level (20.76%) and AUC (31.20%) in line with
its known in vivo α-amylase inhibitory action.Effect of treatment on sucrose tolerance tests in non-
diabetic and diabetic rats
The effects of P. macrocarpa extracts/fractions and
acarbose on sucrose tolerance in NDRs and SDRs are
shown in Table 3 and Figures 5 and 6. From the test
results in NDRs, SFI alone demonstrated a strong inhibi-
tory action against α-glucosidase in vivo, i.e. 17.28% and
15.57% reductions in PBG and AUC respectively, similar
to the effect of acarbose (24.76% and 21.63%; P < 0.05).
The ME and NBF showed weak activity against the en-
zyme in vivo. Results of the tolerance test in SDR
revealed that NBF was the most effective at inhibiting α-
glucosidase action in vivo i.e. 15.08% and 14.23%
reductions in PBG and AUC respectively (P < 0.05). The
in vivo inhibition corresponds to its high inhibitory ac-
tivity observed in the in vitro α-glucosidase test. Al-
though SFI was weak in reducing the PBG within the
Figure 2 Inhibitory effects of extract/fractions of P. macrocarpa fruit pericarp and acarbose on porcine α-amylase activity. The test was
performed in triplicate; values (% enzyme activity) are the mean ± SEM. ME: Methanol extract, NBF: n-Butanol fraction, SFI: Sub-fraction 1.
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curve over the 2 hours by 12.46% (P < 0.05). Acarbose
was potent at reducing the PBG level (23.36%) and AUC
(31.55%) significantly (P < 0.05).Effect of treatments on starch tolerance tests in non-
diabetic and diabetic rats
In NDRs, both PBG and AUC were reduced by the 4
treatments (Table 4 and Figure 7). However, the reduc-
tion in PBG level was only significant in NBF andTable 2 Effect of treatments on blood glucose (PBG) and area
non-diabetic rats (NDRs) and STZ-diabetic rats (SDRs)
Group PBG (mmol/L) % Reduction o
Non-diabetic rats
NC (vehicle) 8.9 ± 0.34
ACAR (10 mg/kg) 6.5 ± 0.32* 26.97
ME (1 g/kg) 7.4 ± 0.31 16.85
NBF (1 g/kg) 7.15 ± 0.18 19.66
SFI (1 g/kg) 6.20 ± 0.15* 30.34
Diabetic rats
DC (vehicle) 21.92 ± 0.8
ACAR (10 mg/kg) 17.37 ± 0.66* 20.76
ME (1 g/kg) 22.05 ± 0.53 -
NBF (1 g/kg) 21.33 ± 1.22 2.69
SFI (1 g/kg) 19.85 ± 1.42 9.44
Values are the mean ± SEM, n = 6, *P < 0.05 vs. control. NC: Normal control, DC: Diab
Sub-fraction 1.acarbose PBG treated groups and for the AUC in the
acarbose treated group (P < 0.05). In SDRs, NBF and SFI
decreased PBG and AUC non-significantly compared
with the DC, whereas ME had no effect on the tolerance
curve (Figure 8).Discussion
α-Glucosidase inhibitors, a group of oral hypoglycaemic
agents (OHA), have proven more useful and beneficial
than other anti-diabetic drugs due to their exceptionalunder the curve (AUC) after glucose loading (4 g/kg) in
f PBG AUC (mmol/L) % Reduction of AUC
14.4 ± 0.32
11.2 ± 0.44* 22.22
12.4 ± 0.48* 13.89
12.08 ± 0.28* 16.11
11.04 ± 0.09* 23.33
39.93 ± 1.75
27.47 ± 0.9* 31.20
40.08 ± 0.74 -
37.05 ± 1.6 7.21
34.58 ± 2.34 13.40
etic control, ACAR: Acarbose, ME: Methanol extract, NBF: n-Butanol fraction, SFI:
Figure 3 Effects of treatments on glucose tolerance after oral glucose administration (2 g/kg) in non-diabetic rats (NDRs). Values are the
mean ± SEM (n = 6), *P < 0.05 vs. control. NC: Normal control, ACAR: Acarbose, ME: Methanol extract, NBF: n-Butanol fraction, SFI: Sub-fraction 1.
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(PPH). In terms of blood glucose lowering action, the α-
glucosidase inhibitors are less effective compared with
most other OHAs. Their singular advantage of averting
the risk of PPH has made them most suitable in combin-
ation with other agents [17]. Therefore, the in vitro and
in vivo α-glucosidase and α-amylase inhibitory effect of P.
macrocarpa, a plant with evidence of strong empirical
anti-diabetic properties, was investigated.Figure 4 Effect of treatments on glucose tolerance after oral glucose
(SDRs). Values are the mean ± SEM (n = 6) *P < 0.05 vs. control. DC: Diabeti
fraction, SFI: Sub-fraction 1.To our knowledge, the present study demonstrates for
the first time the potent inhibitory activity of P. macro-
carpa fruit extract and fractions against α-glucosidase
and α-amylase in vitro. The n-butanol fraction had the
highest inhibitory action against the two enzymes rela-
tive to the methanol extract and the sub-fraction. This
effective inhibitory action of the n-butanol fraction can
be correlated to its high mangiferin composition. An
earlier LC-MS analysis of the three analytes revealed thatadministration (2 g/kg) in streptozotocin-induced diabetic rats
c control, ACAR: Acarbose, ME: Methanol extract, NBF: n-Butanol
Table 3 Effect of treatments on peak blood glucose (PBG) and area under the curve (AUC) after sucrose loading (4 g/kg) in
non-diabetic rats (NDRs) and STZ-diabetic rats (SDRs)
Group PBG (mmol/L) % Reduction of PBG AUC (mmol/L) % Reduction of AUC
Non-diabetic rats
NC (vehicle) 7.35 ± 0.41 13.04 ± 0.54
ACAR (10 mg/kg) 5.53 ± 0.14* 24.76 10.22 ± 0.19* 21.63
ME (1 g/kg) 6.30 ± 0.10 14.29 11.46 ± 0.18 12.12
NBF (1 g/kg) 6.52 ± 0.18 11.29 11.65 ± 0.28 10.66
SFI (1 g/kg) 6.08 ± 0.14 17.28 11.01 ± 0.20* 15.57
Diabetic rats
DC (vehicle) 24.14 ± 1.14 43.71 ± 1.10
ACAR (10 mg/kg) 18.5 ± 0.96* 23.36 29.92 ± 0.78* 31.55
ME (1 g/kg) 21.5 ± 1.10 10.94 40.97 ± 1.66 6.27
NBF (1 g/kg) 20.53 ± 0.9 15.08 37.49 ± 1.45* 14.23
SFI (1 g/kg) 22.58 ± 1.45 6.46 38.27 ± 1.68* 12.46
Values are the mean ± SEM, n = 6, *P < 0.05 vs. control. NC: Normal control, DC: Diabetic control, ACAR: Acarbose, ME: Methanol extract, NBF: n-Butanol fraction, SFI:
Sub-fraction 1.
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was the predominant bio-compound in P. macrocarpa,
occurring at 9.52% in the methanol extract, 33.30% in the
n-butanol fraction and 22.50% in the sub-fraction 1 [14].
Moreover, previously, mangiferin isolated from Salacia spe-
cies, Mangifera indica and Belamcanda chinensis was also
shown to exhibit strong inhibitory activities against α-
glucosidase in vitro [18-20]. Additionally, the antidiabetic
effect of mangiferin in streptozotocin-induced diabetic rats
has been reported [21,22]. The involvement of mangiferin
in the enzyme inhibition was also supported by the fact that
the sub-fraction with the second highest content ofFigure 5 Effect of treatments on sucrose tolerance after oral sucrose
mean ± SEM (n = 6), *P < 0.05 vs. control. NC: Normal control, ACAR: Acarbomangiferin exerted the second highest inhibitory activity.
Contrary to the expected result from activity-guided
assays, the mangiferin content was found to be lower in
SFI, the purer fraction, than NBF. The method required
for processing, including the use of flash column and
thin layer chromatography and treatment with several
solvents, may have resulted in the degradation of
mangiferin, accounting for its relatively low content and
detection in the LC-MS assay.
The observed in vitro α-glucosidase and α-amylase in-
hibitory effects were replicated in the in vivo carbohy-
drate tolerance tests for the most part. The n-butanoladministration (4 g/kg) in non-diabetic rats (NDRs). Values are the
se, ME: Methanol extract, NBF: n-Butanol fraction, SFI: Sub-fraction 1.
Figure 6 Effect of treatments on sucrose tolerance after oral sucrose administration (4 g/kg) in streptozotocin-induced diabetic rats
(SDRs). Values are the mean ± SEM (n = 6), *P < 0.05 vs. control. DC: Diabetic control, ACAR: Acarbose, ME: Methanol extract, NBF: n-Butanol
fraction, SFI: Sub-fraction 1.
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http://www.biomedcentral.com/1472-6882/13/39fraction and sub-fraction 1 significantly reduced the
AUC in streptozotocin-treated diabetic rats after oral su-
crose administration. The extent of the reduction also
corresponded to the mangiferin composition. A similar
observation from a glucose tolerance test with extracts
from young and old leaves and fruits of P. macrocarpa
conducted in non-diabetic animals was reported by
Sugiwati and co-workers [9,10]. Natural products with
properties such as those identified in this study have theTable 4 Effect of treatments on peak blood glucose (PBG) and
in non-diabetic rats (NDRs) and STZ-diabetic rats (SDRs)
Group PBG (mmol/L) % Reduction o
Non-diabetic rats
NC (vehicle) 6.12 ± 0.10
ACAR (10 mg/kg) 4.43 ± 0.11* 27.61
ME (1 g/kg) 5.78 ± 0.39 5.56
NBF (1 g/kg) 5.18 ± 0.08* 15.36
SFI (1 g/kg) 5.97 ± 0.05 2.45
Diabetic rats
DC (vehicle) 22.5 ± 1.02
ACAR (10 mg/kg) 18.7 ± 1.95 16.89
ME (1 g/kg) 22.6 ± 1.03 -
NBF (1 g/kg) 21.1 ± 1.38 6.22
SFI (1 g/kg) 19.1 ± 1.00 15.11
Values are the mean ± SEM, n = 6, *P < 0.05 vs. control. NC: Normal control, DC: Diab
Sub-fraction 1.capacity to delay carbohydrate absorption into the blood
stream by reversibly inhibiting the activity of carbohydrate
digesting enzymes in the small intestinal brush border that
are responsible for the breakdown of oligosaccharides and
disaccharides into monosaccharides suitable for absorp-
tion [23]. Alternatively, some natural products may
function by simply delaying the transfer of glucose from
the stomach to the small intestine, the main site of glu-
cose absorption (delayed gastric emptying rate) [24,25].area under the curve (AUC) after starch loading (4 g/kg)
f PBG AUC (mmol/L) % Reduction of AUC
11.22 ± 0.17
9.10 ± 0.19* 18.89
10.37 ± 0.50 7.58
9.61 ± 0.08 14.35
10.58 ± 0.15 5.70
41.2 ± 1.74
26.1 ± 2.8* 36.65
43.9 ± 2.99 -
35.6 ± 2.32 13.59
33.5 ± 1.5 18.69
etic control, ACAR: Acarbose, ME: Methanol extract, NBF: n-Butanol fraction, SFI:
Figure 7 Effect of treatments on starch tolerance after oral starch administration (3 g/kg) in non-diabetic rats (NDRs). Values are the
mean ± SEM (n = 6), *P < 0.05 vs. control. NC: Normal control, ACAR: Acarbose, ME: Methanol extract, NBF: n-Butanol fraction, SFI: Sub-fraction 1.
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http://www.biomedcentral.com/1472-6882/13/39Consequently, these natural products avert the threat of
hyperglycaemia after meals, and more importantly may
provide glycaemic control without hyperinsulinaemia
and body weight gain. Agents including conventional
drugs that exploit any of the two targets to exert their
anti-diabetic action are of particular interest for the
management and prevention of type II diabetes
mellitus.Figure 8 Effect of treatments on starch tolerance after oral starch adm
(SDRs). Values are the mean ± SEM (n = 6), *P < 0.05 vs. control. DC: Diabet
fraction, SFI: Sub-fraction 1.Conclusions
P. macrocarpa is a traditional medicinal plant with a
long history of use as an anti-diabetic remedy in Asia
Pacific countries. The present study, besides contributing
to the scientific validation of the anti-diabetic properties of
P. macrocarpa, suggests that attenuation of carbohydrate
hydrolysis via inhibition of α-glucosidase and α-amylase ac-
tivities is one mechanism of its hypoglycaemic and anti-inistration (3 g/kg) in streptozotocin-induced diabetic rats
ic control, ACAR: Acarbose, ME: Methanol extract, NBF: n-Butanol
Ali et al. BMC Complementary and Alternative Medicine 2013, 13:39 Page 11 of 11
http://www.biomedcentral.com/1472-6882/13/39hyperglycaemic therapeutic benefits. Moreover, mangiferin,
a compound previously isolated from this plant may be re-
sponsible for the observed enzyme inhibition activity.
Hence, P. macrocarpa is a prospective and veritable source
of natural products for the management of type II diabetes
mellitus.
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